CAMBRIDGE, Mass., Jan. 5, 2026 /PRNewswire/ --MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive ...
Ultragenyx announced significant cognitive improvements in Sanfilippo syndrome type A patients treated with UX111 gene therapy, presented at WORLDSymposium™ 2025. Ultragenyx Pharmaceutical Inc.
In the intent to treat analysis, Dermata saw statistically significant differences in IGA treatment success, inflammatory lesion count, and non-inflammatory lesion count at week 4 (earliest measured ...
*The main analyses of ambulatory BP endpoints include patients with valid ambulatory blood pressure monitoring at both baseline and Week 12, without imputation of missing data. The Phase III Bax24 ...
SALT LAKE CITY, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinical-stage ...
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results